Defibrotide for the Treatment of Severe COVID-19

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT04652115
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Accepted

Interventions

  • Defibrotide — DRUG
    Deibrotide via IV

Study Details

The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19 pneumonia.

Key Dates

Start date
Jan 1, 2021
Status verified
Feb 2026
Primary completion
Jun 1, 2026
Completion
Jan 1, 2027

Study Design

Enrollment
42 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Defibrotide
    Defibrotide IV

Primary Outcome Measure

The rate of adverse event of special interest (bleeding and hypotension) [ Time Frame: Up to 21 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02214
Paul G Richardson, MD
[email protected]
617-632-2127
Paul G Richardson, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
Brigham and Women's Hospital· Boston, MA

Related Studies